Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Isella

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal CancerAdam Lafferty, Alice C O'Farrell, Giorgia Migliardi, et al.
Cell Reports|July 28, 2023
Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomasFrancesca De Bacco, Francesca Orzan, Giovanni Crisafulli, et al.
Nature Communications|March 22, 2022
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestineCarlos Sebastian, Christina Ferrer, Maria Serra, et al.
Science Translational Medicine|August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotypeBarbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Neoplasia (New York, N.Y.)|March 26, 2018
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived XenograftsSimona Corso, Marilisa Cargnelutti, Stefania Durando, et al.
European Journal of Human Genetics : EJHG|July 8, 2026
Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature reviewCéline Jost, Alessandro Mussa, Jean-Emmanuel Kurtz, et al.
Gut|March 26, 2015
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasisHui Ling, Karen Pickard, Cristina Ivan, et al.
Cancer Research|October 6, 2019
A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI TraitsSimona Corso, Claudio Isella, Sara E Bellomo, et al.
Nature Genetics|June 3, 2024
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancerSudhir B Malla, Ryan M Byrne, Maxime W Lafarge, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal CancerAdam Lafferty, Alice C O'Farrell, Giorgia Migliardi, et al.
Cell Reports|July 28, 2023
Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomasFrancesca De Bacco, Francesca Orzan, Giovanni Crisafulli, et al.
Nature Communications|March 22, 2022
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestineCarlos Sebastian, Christina Ferrer, Maria Serra, et al.
Science Translational Medicine|August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotypeBarbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Neoplasia (New York, N.Y.)|March 26, 2018
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived XenograftsSimona Corso, Marilisa Cargnelutti, Stefania Durando, et al.
European Journal of Human Genetics : EJHG|July 8, 2026
Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature reviewCéline Jost, Alessandro Mussa, Jean-Emmanuel Kurtz, et al.
Gut|March 26, 2015
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasisHui Ling, Karen Pickard, Cristina Ivan, et al.
Cancer Research|October 6, 2019
A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI TraitsSimona Corso, Claudio Isella, Sara E Bellomo, et al.
Nature Genetics|June 3, 2024
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancerSudhir B Malla, Ryan M Byrne, Maxime W Lafarge, et al.
Pageof 7